Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Revance Therapeutics (NASDAQ: RVNC) will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close. A conference call and live webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide a corporate update.
U.S. callers can dial (833) 470-1428, while international callers can dial (929) 526-1599, using conference ID 218406. The webcast will be accessible through the investor relations section of Revance's website and will be available for replay from August 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET to November 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET. Registration for the replay is required via the webcast link on the events page. The webcast will remain available for 90 days post-event.
Revance Therapeutics (NASDAQ: RVNC) rilascerà i risultati finanziari del secondo trimestre 2024 il giovedì 8 agosto 2024, dopo la chiusura del mercato. Seguirà una teleconferenza e un webcast dal vivo alle 13:30 PT / 16:30 ET per discutere i risultati e fornire un aggiornamento aziendale.
I chiamanti statunitensi possono comporre il numero (833) 470-1428, mentre i chiamanti internazionali possono chiamare il (929) 526-1599, utilizzando l'ID della conferenza 218406. Il webcast sarà accessibile attraverso la sezione relazioni con gli investitori del sito web di Revance e sarà disponibile per la riproduzione dal 8 agosto 2024 alle 16:30 PT / 19:30 ET fino all'8 novembre 2024 alle 16:30 PT / 19:30 ET. La registrazione per la riproduzione è richiesta tramite il link del webcast nella pagina eventi. Il webcast rimarrà disponibile per 90 giorni dopo l'evento.
Revance Therapeutics (NASDAQ: RVNC) publicará sus resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, después del cierre del mercado. Seguirá una llamada de conferencia y un webcast en vivo a la 1:30 p. m. PT / 4:30 p. m. ET para discutir los resultados y proporcionar una actualización corporativa.
Los llamadores de EE. UU. pueden marcar (833) 470-1428, mientras que los llamadores internacionales pueden marcar (929) 526-1599, utilizando el ID de conferencia 218406. El webcast será accesible a través de la sección de relaciones con inversores del sitio web de Revance y estará disponible para reproducción desde el 8 de agosto de 2024 a las 4:30 p. m. PT / 7:30 p. m. ET hasta el 8 de noviembre de 2024 a las 4:30 p. m. PT / 7:30 p. m. ET. Se requiere registro para la reproducción a través del enlace del webcast en la página de eventos. El webcast seguirá disponible durante 90 días después del evento.
레방스 테라퓨틱스 (NASDAQ: RVNC)는 2024년 8월 8일 목요일, 시장 종료 후 2024년 2분기 재무 결과를 발표할 예정입니다. 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 실시간 웹캐스트가 오후 1:30 PT / 오후 4:30 ET에 뒤따릅니다.
미국 전화자는 (833) 470-1428로 전화할 수 있고, 국제 전화자는 (929) 526-1599로 전화할 수 있으며, 컨퍼런스 ID 218406를 사용해야 합니다. 웹캐스트는 레방스의 투자자 관계 웹사이트에서 접근할 수 있으며, 2024년 8월 8일 오후 4:30 PT / 오후 7:30 ET부터 2024년 11월 8일 오후 4:30 PT / 오후 7:30 ET까지 재생할 수 있습니다. 재생 등록은 이벤트 페이지의 웹캐스트 링크를 통해 요구됩니다. 웹캐스트는 이벤트 후 90일 동안 제공됩니다.
Revance Therapeutics (NASDAQ: RVNC) annoncera ses résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024, après la clôture du marché. Une conférence téléphonique et un webinaire en direct suivront à 13h30 PT / 16h30 ET pour discuter des résultats et fournir une mise à jour entreprise.
Les appelants américains peuvent composer le (833) 470-1428, tandis que les appelants internationaux peuvent composer le (929) 526-1599, en utilisant l'ID de conférence 218406. Le webinaire sera accessible via la section relations investisseurs du site web de Revance et sera disponible en rediffusion du 8 août 2024 à 16h30 PT / 19h30 ET au 8 novembre 2024 à 16h30 PT / 19h30 ET. L'inscription pour la rediffusion est requise via le lien du webinaire sur la page des événements. Le webinaire restera disponible pendant 90 jours après l'événement.
Revance Therapeutics (NASDAQ: RVNC) wird am Donnerstag, den 8. August 2024, nach Börsenschluss die finanziellen Ergebnisse des zweiten Quartals 2024 veröffentlichen. Anschließend wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
US-Anrufer können die Nummer (833) 470-1428 wählen, während internationale Anrufer (929) 526-1599 wählen können, unter Verwendung von Konferenz-ID 218406. Der Webcast wird über den Bereich Investor Relations der Revance-Website zugänglich sein und wird vom 8. August 2024, 16:30 Uhr PT / 19:30 Uhr ET bis zum 8. November 2024, 16:30 Uhr PT / 19:30 Uhr ET zur Wiederholung verfügbar sein. Eine Registrierung für die Wiederholung ist über den Link zum Webcast auf der Veranstaltungsseite erforderlich. Der Webcast bleibt 90 Tage nach der Veranstaltung verfügbar.
- Revance is set to release its Q2 2024 financial results, providing transparency and potentially positive financial insights.
- Scheduled conference call and webcast indicate proactive investor communication and engagement.
- None.
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET.
Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for
A webcast replay will be available beginning August 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET to November 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s
Revance’s global headquarters and experience center is located in
“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801872014/en/
Investors
Laurence Watts, 619-916-7620
laurence@newstreetir.com
Media
Revance@evolvemkd.com
Source: Revance Therapeutics, Inc.
FAQ
When will Revance release its Q2 2024 financial results?
What time is the Revance Q2 2024 financial results conference call?
How can I access the Revance Q2 2024 financial results webcast?
What is the conference ID for the Revance Q2 2024 financial results call?
How long will the Revance Q2 2024 financial results webcast be available?
